Crystal Meth Summit in Canada wants drug re-classified

NewsGuard 100/100 Score

Crystal meth, a powerful addictive drug has now become such a problem in Canada that law enforcement officials met in Regina last week for a Crystal Meth Summit.

Saskatchewan Premiere Lorne Calvert said as a result of the meeting that she beleived real progress could be made.

Crystal meth has swept across the western United States, and is now the problem has spread to Canada's western provinces.

Policy makers are saying that the drug should be re-classified and put into the same category as cocaine and heroin.

At present Crystal meth is classified as a category 3 drug, while cannabis is category 2 and heroin is category 1. The maximum penalty for a category 1 offence is life imprisonment.

There are currently very few programs that users can enter in order to break their addiction, and an increased classification might mean more treatment programs for addicts by raising awareness of the drug.

Drug worker Steve Paulson, who works for Teen Challenge, an organization that helps youths with drug addiction problems says youngsters are dying while they wait to access recovery programs.

Crystal meth's popularity is attributed to the ease with which it can be made. The chemicals can be found in any drug store, and the main ingredient is in cold medicines.

The government has proposed stricter controls for such chemicals, adding six specific chemicals that would require a license to produce and distribute.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccines targeting chronic diseases show promise in combatting age-related conditions